Form 4: Mineralys Therapeutics Director Brian Taylor Slingsby Acquires Additional Shares

Brian Taylor Slingsby, a director and 10% owner of Mineralys Therapeutics, acquired 259,259 shares of common stock at $13.50 per share on March 13, 2025.

Summary

• On March 13, 2025, Brian Taylor Slingsby, a director and 10% owner of Mineralys Therapeutics, acquired 259,259 shares of common stock at a price of $13.50 per share.
• Following this transaction, Mr. Slingsby indirectly owns 8,903,838 shares through Catalys Pacific Fund, LP.
• Catalys Pacific Fund, LP is the direct holder of these securities.
• Catalys Pacific Fund GP, LP is the general partner of Catalys Pacific Fund, LP.
• Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, which is the general partner of Catalys Pacific Fund GP, LP.
• Mr. Slingsby disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The purchase itself could be interpreted as slightly positive, but the document is primarily informational.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders.

Stakeholder Impact

• The transaction could influence investor sentiment towards Mineralys Therapeutics.

Key Dates

Keywords

Mineralys Therapeutics, Brian Taylor Slingsby, Catalys Pacific Fund, share acquisition, Form 4, beneficial ownership, director, 10% owner